- Home
- SPHL vs RNAZ Comparison
SPHL vs RNAZ Comparison
Compare SPHL & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHL
- RNAZ
- Stock Information
- Founded
- SPHL 2002
- RNAZ 2016
- Country
- SPHL Singapore
- RNAZ United States
- Employees
- SPHL N/A
- RNAZ N/A
- Industry
- SPHL Homebuilding
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- SPHL Consumer Discretionary
- RNAZ Health Care
- Exchange
- SPHL Nasdaq
- RNAZ Nasdaq
- Market Cap
- SPHL 7.3M
- RNAZ 7.2M
- IPO Year
- SPHL 2024
- RNAZ 2021
- Fundamental
- Price
- SPHL $0.44
- RNAZ $0.56
- Analyst Decision
- SPHL
- RNAZ Strong Buy
- Analyst Count
- SPHL 0
- RNAZ 1
- Target Price
- SPHL N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- SPHL 1.4M
- RNAZ 16.6M
- Earning Date
- SPHL 02-21-2025
- RNAZ 05-14-2025
- Dividend Yield
- SPHL N/A
- RNAZ N/A
- EPS Growth
- SPHL 413.11
- RNAZ N/A
- EPS
- SPHL 0.09
- RNAZ N/A
- Revenue
- SPHL $11,020,429.00
- RNAZ N/A
- Revenue This Year
- SPHL N/A
- RNAZ $180.81
- Revenue Next Year
- SPHL N/A
- RNAZ N/A
- P/E Ratio
- SPHL $5.62
- RNAZ N/A
- Revenue Growth
- SPHL 112.84
- RNAZ N/A
- 52 Week Low
- SPHL $0.42
- RNAZ $0.43
- 52 Week High
- SPHL $7.80
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- SPHL N/A
- RNAZ 27.66
- Support Level
- SPHL N/A
- RNAZ $0.43
- Resistance Level
- SPHL N/A
- RNAZ $0.67
- Average True Range (ATR)
- SPHL 0.00
- RNAZ 0.17
- MACD
- SPHL 0.00
- RNAZ 0.19
- Stochastic Oscillator
- SPHL 0.00
- RNAZ 4.75
About SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.